A client receiving vedolizumab for ulcerative colitis develops new findings. Which action should the nurse take first?
Chart/Exhibit
Choose your responses, then check the answer.
Explanation
Jaundice with marked transaminase and bilirubin elevation plus fever and respiratory symptoms requires prompt evaluation for significant liver injury and active infection before further vedolizumab exposure.
Quick answer Act on hepatic injury and active infection before the next biologic dose.
Why this is correct Vedolizumab should be discontinued for jaundice or other evidence of significant liver injury, and serious infection requires treatment review. Immunization planning does not replace evaluation of an active febrile illness.
Easy analogy or mental picture Use a closed medication-safety loop: identify the immune or cytotoxic exposure, connect the new findings, interrupt further harm, stabilize the client, and verify the response over time.
Memory hook Exposure, immune effect, organ toxicity, infection risk, immediate action, and serial reassessment.
NCLEX decision rule Choose the action that reduces the most immediate medication-related risk while preserving diagnostic evaluation and authorized treatment.
Why the other choices are wrong Options that continue the exposure, treat only one symptom, or delay reassessment leave the toxic or infectious process active.
References
1DailyMed: ENTYVIO (vedolizumab)Serious infection, neurologic monitoring for PML, liver injury, immunization review, and treatment discontinuation
Oncology, transplant, and biologic safety reviewVerify the indication, immune status, infection screen, interacting medicines, current organ findings, authorized action, and measurable follow-up.